Eur Rev Med Pharmacol Sci 2018; 22 (11): 3617-3625

DOI: 10.26355/eurrev_201806_15189

Oral administration of a curcumin-phospholipid formulation (Meriva®) for treatment of chronic diabetic macular edema: a pilot study

F. Mazzolani, S. Togni, L. Giacomelli, R. Eggenhoffner, F. Franceschi

Private Practice, Bergamo, Italy. fabio.mazzolani@email.it


OBJECTIVE: The purpose of this open-label study was to investigate the effect of a curcumin-phospholipid lecithin formulation (Meriva®) on visual acuity and optical coherence tomography (OCT) retinal thickness in patients with chronic diabetic macular edema.

PATIENTS AND METHODS: Curcumin-phospholipid lecithin formulation (Meriva®, Indena S.p.A, Milan, Italy) was administered as tablets (Norflo®, Eye Pharma, Genoa, Italy) twice a day. Visual acuity and macular edema as measured by OCT before and after curcumin-phospholipid formulation treatment were assessed.

RESULTS: The study included 12 eyes from 11 patients who completed at least a 3-month follow-up period. After 3 months of therapy, no eyes showed reduction in visual acuity, 16% showed stabilization, and 84% showed improvement. The improvement was statistically significant (p = 0.0072). After 3 months of therapy, 92% of eyes showed reduction of macula edema, 8% showed stabilization, and 0% showed an increase (p = 0.009).

CONCLUSIONS: Our results, albeit preliminary, suggest that a curcumin-phospholipid formulation (Meriva®), administered as Norflo® tablets, may be feasible in the improvement of visual acuity and reduction of macular edema in patients with diabetic retinopathy.

Free PDF Download

To cite this article

F. Mazzolani, S. Togni, L. Giacomelli, R. Eggenhoffner, F. Franceschi
Oral administration of a curcumin-phospholipid formulation (Meriva®) for treatment of chronic diabetic macular edema: a pilot study

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 11
Pages: 3617-3625
DOI: 10.26355/eurrev_201806_15189